135 related articles for article (PubMed ID: 21046120)
1. HsMAD2 mRNA expression may be a predictor of sensitivity to paclitaxel and survival in neuroblastoma.
Otake K; Uchida K; Tanaka K; Koike Y; Inoue M; Matsushita K; Ueeda M; Hashimoto K; Kitajima T; Komada Y; Kusunoki M
Pediatr Surg Int; 2011 Feb; 27(2):217-23. PubMed ID: 21046120
[TBL] [Abstract][Full Text] [Related]
2. Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy.
Tanaka K; Mohri Y; Ohi M; Yokoe T; Koike Y; Morimoto Y; Miki C; Tonouchi H; Kusunoki M
Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):639-46. PubMed ID: 18691855
[TBL] [Abstract][Full Text] [Related]
3. [Expression of human spindle mitosis arrest deficiency gene in spontaneous abortion embryo tissues].
Cai Y; Wang J; Yuan TX; Shi Q; Weng YG; Wang YX; Jiang HY; Liu ZJ
Zhonghua Fu Chan Ke Za Zhi; 2008 May; 43(5):346-51. PubMed ID: 18953867
[TBL] [Abstract][Full Text] [Related]
4. Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer.
Hernando E; Orlow I; Liberal V; Nohales G; Benezra R; Cordon-Cardo C
Int J Cancer; 2001 Jul; 95(4):223-7. PubMed ID: 11400114
[TBL] [Abstract][Full Text] [Related]
5. Mitotic checkpoint protein hsMAD2 as a marker predicting liver metastasis of human gastric cancers.
Tanaka K; Nishioka J; Kato K; Nakamura A; Mouri T; Miki C; Kusunoki M; Nobori T
Jpn J Cancer Res; 2001 Sep; 92(9):952-8. PubMed ID: 11572763
[TBL] [Abstract][Full Text] [Related]
6. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional abnormality of the hsMAD2 mitotic checkpoint gene is a potential link to hepatocellular carcinogenesis.
Jeong SJ; Shin HJ; Kim SJ; Ha GH; Cho BI; Baek KH; Kim CM; Lee CW
Cancer Res; 2004 Dec; 64(23):8666-73. PubMed ID: 15574775
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of CES2 RNA expression in neuroblastoma.
Uchida K; Otake K; Tanaka K; Hashimoto K; Saigusa S; Matsushita K; Koike Y; Inoue M; Ueeda M; Okugawa Y; Inoue Y; Mohri Y; Kusunoki M
J Pediatr Surg; 2013 Mar; 48(3):502-9. PubMed ID: 23480903
[TBL] [Abstract][Full Text] [Related]
10. Mutational inactivation of mitotic checkpoint genes, hsMAD2 and hBUB1, is rare in sporadic digestive tract cancers.
Imai Y; Shiratori Y; Kato N; Inoue T; Omata M
Jpn J Cancer Res; 1999 Aug; 90(8):837-40. PubMed ID: 10543255
[TBL] [Abstract][Full Text] [Related]
11. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
12. Shc family expression in neuroblastoma: high expression of shcC is associated with a poor prognosis in advanced neuroblastoma.
Terui E; Matsunaga T; Yoshida H; Kouchi K; Kuroda H; Hishiki T; Saito T; Yamada S; Shirasawa H; Ohnuma N
Clin Cancer Res; 2005 May; 11(9):3280-7. PubMed ID: 15867224
[TBL] [Abstract][Full Text] [Related]
13. The high level of hCDC10 gene expression in neuroblastoma may be associated with favorable characteristics of the tumor.
Nagata T; Takahashi Y; Asai S; Ishii Y; Mugishima H; Suzuki T; Chin M; Harada K; Koshinaga S; Ishikawa K
J Surg Res; 2000 Aug; 92(2):267-75. PubMed ID: 10896833
[TBL] [Abstract][Full Text] [Related]
14. Effect of Mad2 on paclitaxel-induced cell death in ovarian cancer cells.
Hao X; Zhou Z; Ye S; Zhou T; Lu Y; Ma D; Wang S
J Huazhong Univ Sci Technolog Med Sci; 2010 Oct; 30(5):620-5. PubMed ID: 21063845
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of the candidate tumor suppressor gene ING1 is associated with poor prognosis in advanced neuroblastomas.
Takahashi M; Ozaki T; Todo S; Nakagawara A
Oncol Rep; 2004 Oct; 12(4):811-6. PubMed ID: 15375504
[TBL] [Abstract][Full Text] [Related]
16. L1 is associated with favorable outcome in neuroblastomas in contrast to adult tumors.
Wachowiak R; Fiegel HC; Kaifi JT; Quaas A; Krickhahn A; Schurr PG; Erttmann R; Schachner M; Kluth D; Sauter G; Izbicki JR
Ann Surg Oncol; 2007 Dec; 14(12):3575-80. PubMed ID: 17917782
[TBL] [Abstract][Full Text] [Related]
17. [Neuroblastoma in children. Results of the treatment and analysis of selected prognostic factors].
Januszkiewicz D; Lastowska M; Zieliński W
Nowotwory; 1990; 40(2):143-8. PubMed ID: 2274426
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the risk factor for the poor prognosis of localized neuroblastoma after the surgical.
Zhou K; Li XL; Pan J; Xu JZ; Wang J
Medicine (Baltimore); 2018 Oct; 97(40):e12718. PubMed ID: 30290678
[TBL] [Abstract][Full Text] [Related]
19. Association of N-myc amplification with neuroblastoma: the Australian and New Zealand experience.
Telford DJ; Kavallaris M; White L; Norris MD; Brian MJ; Stewart BW
J Paediatr Child Health; 1992 Feb; 28(1):58-63. PubMed ID: 1554517
[TBL] [Abstract][Full Text] [Related]
20. Repp86 expression and outcome in patients with neuroblastoma.
Krams M; Heidebrecht HJ; Hero B; Berthold F; Harms D; Parwaresch R; Rudolph P
J Clin Oncol; 2003 May; 21(9):1810-8. PubMed ID: 12721258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
